NEW YORK, August 16, 2016 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com follows four Drug Manufacturing equities, namely, Amarin Corp. PLC (NASDAQ: AMRN), Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Global prescription drug sales are expected to increase 3% this year despite drug-price debates and cost-control pressures. You can access of our complimentary research reports on these stocks now at:
Dublin, Ireland-based Amarin Corp. PLC's shares gained 3.26%, closing Monday's trading session at $3.17. The stock recorded a trading volume of 2.86 million shares, which was above its three months average volume of 2.37 million shares. The Company's shares have surged 37.23% in the last month, 89.82% in the previous three months, and 67.72% since the start of this year. The stock is trading 31.48% above its 50-day moving average and 68.23% above its 200-day moving average. Additionally, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 66.84.
On August 11th, 2016, Amarin announced the pricing of an underwritten public offering of 21,100,000 American Depositary Shares ("ADSs") at a price to the public of $2.85 per ADS. The net proceeds to the company from this offering are expected to be approximately $56.1 million. The offering is expected to close on or about August 16th, 2016, subject to customary closing conditions. Visit us today and download your complete report on AMRN for free at:
On Monday, shares in Newark, California headquartered Depomed Inc. recorded a trading volume of 849,979 shares. The stock fell 0.14%, ending the day at $21.45. The Company's shares have advanced 14.04% in the last month, 16.70% over the previous three months, and 18.31% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.12% and 20.92%, respectively. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 65.54.
On July 27th, 2016, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'.
On August 4th, 2016, Depomed reported that Q2 2016 revenues were $117 million up 23% compared to $95 million for Q2 2015. The company reported net loss of $10.54 million, or $0.17 per basic and diluted share, compared to net loss of $21.65, or $0.36 per basic and diluted share, in the year ago quarter. The complimentary research report on DEPO can be accessed at:
Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock finished the day 1.11% higher at $126.58 and with a total volume of 334,519 shares traded. The Company's shares have gained 14.29% in the last one month and 14.43% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 12.20% and 0.16%, respectively. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 66.48.
On July 28th, 2016, United Therapeutics reported revenues of $412.6, up 18.8% compared to revenue of $347.2 in the same period in 2015. The company reported net income of $206.1 for the quarter ended June 30, 2016, higher by 107.8% compared to $99.2 million in the prior year quarter. Register for free on Stock-Callers.com and download the PDF research report on UTHR at:
Shares in Rockville, Maryland headquartered Sucampo Pharmaceuticals Inc. ended yesterday's session 0.52% higher at $11.67. The stock recorded a trading volume of 341,852 shares. The Company's shares have advanced 4.20% in the last one month and 5.04% in the previous three months. The stock is trading 2.41% above its 50-day moving average. Moreover, shares of Sucampo Pharmaceuticals, which focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the US, Japan, Switzerland, and internationally, have an RSI of 50.83.
On August 3rd, 2016, Sucampo reported y-o-y total revenue growth of 49% to $52.0 million, for the three months ended June 30, 2016. Product sales revenue increased to $28.4 million, representing 96% y-o-y growth, and product royalty revenue grew 16% year-over-year to $18.7 million. Sucampo reported a GAAP net loss of $0.8 million, or ($0.02) per diluted share, during Q2 2016, compared to net income of $9.6 million, or $0.21 per diluted share, during Q2 2015.
On August 04th, 2016, research firm Mizuho downgraded the Company's stock rating from 'Buy' to 'Neutral', issuing a target price of $13 per share. Get free access to your research report on SCMP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA